Cyclacel Q3 net loss $2.0M, cash $3.0M; Nasdaq extension to Dec 24; going concern doubt

Bio Green Med Solution, Inc.

2025-Q3 EPS reported -$490.01 revenue$43,000

Net loss $2.0M for Q3 2024 vs $6.0M a year ago; cash $3.0M as of Sept 30, 2024.
R&D expenses fell to $1.0M from $5.2M; fadraciclib R&D $0.9M vs $3.6M.
Nasdaq granted extension to Dec 24, 2024 to regain minimum stockholders' equity compliance.
Substantial doubt about going concern; may curtail operations or file for bankruptcy if funding not secured.
Initial safety/efficacy data from 12 patients in fadraciclib Phase 2 cohort presented at Triple Meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.